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Introduction
============

Acute pancreatitis is a serious condition that often leads to hospital admission and even death. Important risk factors for acute pancreatitis include gallstones, alcohol use, older age, black race, smoking, obesity, and type 2 diabetes.[@ref1] Exposure to certain drugs is also associated with acute pancreatitis.[@ref1] Glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors are two classes of incretin based treatments for type 2 diabetes mellitus. Evidence from randomised controlled trials has shown that GLP-1 agonists effectively lower glycated haemoglobin (HbA1c) by about 1%,[@ref2] reduce body weight, and rarely cause hypoglycaemia when used as monotherapy[@ref3] [@ref4]; DDP-4 inhibitors have intermediate efficacy regarding glucose control[@ref5] with no impact on body weight and a low risk of hypoglycaemia.[@ref3] [@ref6] The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommends the consideration of DPP-4 inhibitors and GLP agonists as second line treatment options.[@ref6] [@ref7]

In 2008, the US Food and Drug Administration (FDA) warned of a strong temporal association between exenatide and pancreatitis on the basis of 30 case reports of acute pancreatitis.[@ref8] In 2009, the FDA notified healthcare professionals and patients of revisions to the prescribing information for Januvia (sitagliptin) and Janumet (sitagliptin/metformin) after announcing the observation of 88 post-marketing cases of acute pancreatitis.[@ref9] In 2012, one consumer group in the United States called for the withdrawal of liraglutide[@ref10] and cautioned that liraglutide is associated with higher than expected rates of pancreatitis, thyroid cancer, and kidney failure based on the following statement from FDA reviewers: "in clinical trials patients taking liraglutide had a risk of pancreatitis that was 3.7 fold higher than the risk in patients taking other antidiabetes drugs." In 2013, the concerns regarding the risk of pancreatitis and pancreatic cancer continued to grow, resulting in international debate.[@ref11] [@ref12] The *BMJ* has published several commentaries discussing the potential risk of pancreatitis and implications of using incretin based drugs.[@ref13] [@ref14] [@ref15] [@ref16] [@ref17] The FDA also has announced ongoing efforts to assess the risk of pancreatic associated with incretins.[@ref18] Yet the definitive recommendations regarding the risk are not available.

Findings from animal studies have been inconsistent. Some showed that exenatide seemed to increase inflammation of pancreatic acinar cells[@ref19] and formation of pancreatic intraepithelial neoplasia[@ref20]; sitagliptin increased pancreatic ductal turnover and ductal metaplasia.[@ref21] Others suggested that exenatide improved chemically induced pancreatitis in normal and diabetic rodents[@ref22] and that liraglutide induced cytokines with anti-inflammatory effects.[@ref23] Another study found that liraglutide did not induce pancreatitis in mice, rats, or monkeys when it was given for up to two years and at exposure concentrations up to 60 times higher than in used in humans.[@ref24]

Results from drug safety surveillance systems have been more concerning. The evidence to support a causal relation between incretin based drugs and pancreatitis is weak. Most safety data have been acquired through the FDA adverse event reporting system (AERS),[@ref8] [@ref9] [@ref25] by which an appropriate selection of control and collection of information regarding the exposure and confounding factors is challenging. Because of ongoing safety concerns, there is a clear need for a rigorous evaluation of the safety of GLP-1 agonists and DPP-4 inhibitors. We conducted a systematic review of randomised and non-randomised studies to provide a comprehensive assessment regarding the risk of pancreatitis associated with GLP-1 agonists and DPP-4 inhibitors relative to placebo or active drugs.

Methods
=======

Eligibility criteria
--------------------

We included randomised and non-randomised controlled trials, prospective and retrospective cohort studies, and case-control studies that enrolled adult patients with type 2 diabetes mellitus; included an unconfounded comparison of GLP-1 agonists or DPP-4 inhibitors against placebo, lifestyle modification, or active antidiabetic drugs; followed up patients for at least 12 weeks (not applicable for case-control studies); and explicitly reported event data on pancreatitis.

To be classified as an unconfounded comparison, we required that planned interventions were identical between treatment and control groups except the GLP-1 agonists or DDP-4 inhibitors under consideration. We also required that authors clearly and explicitly reported numbers of pancreatitis events in all treatment groups under consideration.

Literature search
-----------------

We searched Medline, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) up to March 2013 for published studies without language restrictions. We used both MeSH and free text terms to identify relevant articles. An information expert (DP) developed the search strategy (appendix 1). At the time of searching, we planned to investigate the effect of incretin treatments on people with and without on diabetes. We thus included search terms defining incretin drugs and study designs only.

We also searched ClinicalTrials.gov to identify additional eligible clinical trials. This trial registry documents all drug trials other than phase I studies as required by Section 801 of the US Food and Drug Administration Amendments Act (FDAAA 801)[@ref26] and typically includes extensive lists of adverse events.[@ref27] This provides important information regarding data on pancreatitis. We searched generic names of each individual drug to ensure high sensitivity. We undertook the search of ClinicalTrials.gov in August 2013 to ensure that data from previously published trials were updated on the registry. We limited our search to those trials labelled as "completed" and for which results were available.

Study process
-------------

We developed standardised pilot-tested forms together with detailed instructions for screening of abstracts and full text, risk of bias assessment, and data collection. Pairs of reviewers with training in research methods, independently and in duplicate, screened study reports for eligibility, assessed risk of bias, and collected data from each eligible study. Reviewers dealt with discrepancies through discussion or, if required, adjudication by a third reviewer (XS).

Risk of bias assessment
-----------------------

We used a modified version of Cochrane Collaboration's tool[@ref28] to assess the risk of bias of randomised controlled trials. We considered random sequence generation; allocation concealment; blinding of participants, caregivers, and outcome (that is, pancreatitis) assessors; adjudication of pancreatitis events; prognostic balance between treatment groups; and selective outcome reporting. In assessing the risk of bias with blinding, our modified instrument removed the "unclear" option for the assessment of blinding, an approach we have previously validated.[@ref29]

We used a modified version of the Newcastle-Ottawa quality assessment scale[@ref30] to assess the risk of bias in cohort and case-control studies. For cohort studies, we removed the item regarding representativeness of sample and the item "was the follow-up long enough?" as these items relate to applicability of results. For case-control studies, we also removed the item "representativeness of the cases." For both types of studies, we added two items, one dealing with ascertainment of type 2 diabetes and another with ascertaining confounding variables. We did not assess publication bias because of the low power associated with studies of rare events.

Data collection
---------------

From eligible randomised controlled trials we collected information on study characteristics (study design, sample size, number of treatment groups, length and design (such as variable or fixed) of follow-up, funding source, registry number, whether trials were international and, if so, countries involved, number of study sites, and study phase); patient characteristics (sex, age, duration of type 2 diabetes, baseline HbA1c concentrations, body mass index (BMI), and fasting plasma glucose); interventions (drugs commonly used across all groups (baseline treatment), incretin treatment, control group, dose, intensity, and duration of treatment); pancreatitis events in each of the treatment groups; and number of patients included for analyses in each of the treatment groups (that is, considered as a safety set).

For extension randomised controlled trials, in which treatment assignments were switched (for example, patients in placebo group started receiving incretins), we documented only the outcome data before that point. For multiple reports of the same trial, we collated all data into a single study.[@ref31] If outcome data for pancreatitis were reported at multiple follow-up points, we used data from the longest follow-up.

For observational studies, we documented information as for randomised controlled trials, when applicable. Additionally, we collected information regarding study design (such as retrospective cohort study), sources of data (such as claims data), method of ascertaining type 2 diabetes status (such as ICD (international classification of diseases) code), exposures (such as incretins, and such exposure variables as age), method of adjustment for confounding (such as adjustment or matching, and variables used for these techniques), and follow-up. We also documented unadjusted and adjusted results, in addition to raw event data and exposure time.

Data analysis
-------------

We analysed randomised controlled trials and observational studies separately. For randomised trials, we assessed heterogeneity between studies using a χ^2^ test and the I^2^ statistic. We pooled trials using Peto's methods[@ref32] [@ref33] and reported pooled Peto odds ratios and their associated 95% confidence intervals. P\<0.05 was considered significant. We explored sources of heterogeneity with four a priori subgroup hypotheses: type of incretin (GLP-1 agonists *v* control; DPP-4 inhibitors *v* control); type of control (incretin *v* placebo, incretin *v* active treatment); length of follow-up (incretin *v* control by subgroup of ≤26 weeks, 26-52 weeks, \>52 weeks); and mode of treatment (incretin monotherapy *v* control, incretin add-on/combination treatment *v* control), and a post hoc subgroup analysis of different incretins. We undertook sensitivity analyses by using alternative effect measures (odds ratio *v* relative risk), pooling methods (Peto methods *v* Mantel-Haenszel method), and consideration on heterogeneity (random *v* fixed effect).

We qualitatively analysed the data from observational studies because of differences in outcome measures, exposures (that is, drug under consideration), and forms of outcome data (that is, adjusted *v* unadjusted data; hazard ratio *v* incidence rate ratio). We reported the results according to meta-analysis of observational studies in epidemiology (MOOSE)[@ref34] and preferred reporting items for systematic reviews and meta-analyses (PRISMA).[@ref35]

Results
=======

Our search yielded 7432 potentially relevant reports. After screening titles and abstracts, we retrieved 468 reports for full text screening. Fifty nine studies, including 55 randomised controlled trials[@ref36] [@ref37] [@ref38] [@ref39] [@ref40] [@ref41] [@ref42] [@ref43] [@ref44] [@ref45] [@ref46] [@ref47] [@ref48] [@ref49] [@ref50] [@ref51] [@ref52] [@ref53] [@ref54] [@ref55] [@ref56] [@ref57] [@ref58] [@ref59] [@ref60] [@ref61] [@ref62] [@ref63] [@ref64] [@ref65] [@ref66] [@ref67] [@ref68] [@ref69] [@ref70] [@ref71] [@ref72] [@ref73] [@ref74] [@ref75] [@ref76] [@ref77] [@ref78] [@ref79] [@ref80] [@ref81] [@ref82] [@ref83] [@ref84] [@ref85] [@ref86] [@ref87] [@ref88] [@ref89] [@ref90] (40 from journals and 15 from the trial registry) reported in 61 reports, three cohort studies,[@ref91] [@ref92] [@ref93] and one case-control study[@ref94] were eligible for inclusion (fig 1[](#fig1){ref-type="fig"}). Eight months after our formal search (November 2013), however, an additional large case-control study[@ref95] was published. We therefore also included this study, resulting in inclusion of two case-control studies. These studies recruited 353 639 patients, including 33 350 from randomised controlled trials and 320 289 from observational studies. Three other retrospective cohort studies also examined risk of pancreatitis with incretin drugs[@ref96] [@ref97] [@ref98]; they did not explicitly limit patients to those with type 2 diabetes mellitus and were therefore excluded (appendix 2).

![**Fig 1** Flow chart of article selection. \*Data from ClinicalTrials.gov](lili017292.f1_default){#fig1}

Evidence from randomised controlled trials
------------------------------------------

The 55 randomised controlled trials---all industry funded---were conducted in 2-49 (median 11) countries and 3-268 (median 110) study sites; 45 (82%) were international and 44 (80%) were phase III studies. The length of follow-up ranged from 12 to 234 weeks. The trials enrolled 69 to 1615 patients (total 33 350), with a mean age range of 49.7-66.5, mean BMI range of 24.5-36.7, mean baseline HbA1c range of 7.3-9.8%, mean fasting plasma glucose range of 7.7-11.3 mmol/L, and mean duration of diabetes range of 1-16.7 years (table 1[](#tbl1){ref-type="table"}). None of the studies explicitly mentioned their criteria for diagnosis of pancreatitis.

###### 

 Characteristics of randomised controlled trials of incretin treatment in patients with type 2 diabetes mellitus

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)              International study   No of countries involved   No of study sites   Study phase   Total No of patients   No of groups   Follow up (weeks)   No (%) male   Mean age (years)   Mean BMI   Mean HbA1c (%)   Mean FPG (mmol/L)   Mean diabetes duration\
                                                                                                                                                                                                                                                           (years)
  -------------------------- --------------------- -------------------------- ------------------- ------------- ---------------------- -------------- ------------------- ------------- ------------------ ---------- ---------------- ------------------- -------------------------
  Araki (2013)^36^           No                    1                          47                  III           561                    4              12                  395 (70.4)    60                 25         8                9.1                 286 (51.0)\*

  Barnett (2012)^37^         Yes                   7                          53                  III           227                    2              18                  88 (38.8)     56.5               29.5       8.1              10.1                165 (75.0)\*

  Bergenstal (2010)^38^      Yes                   3                          72                  III           514                    3              26                  254 (51.7)    52.3               32         8.5              9.1                 5.7

  Bunck (2009)^39^           Yes                   3                          3                   III           69                     2              52                  45 (65.2)     58.4               30.5       7.5              9.2                 4.9

  Buse (2011)^40^            Yes                   5                          59                  III           261                    2              30                  148 (57.1)    59                 33.5       8.4              8.1                 12

  Chacra (2011)^41^          Yes                   NR                         NR                  III           768                    3              76                  346 (45.1)    55.1               29         8.4              9.6                 6.9

  Diamant (2010)^42^         Yes                   16                         72                  III           467                    2              26                  243 (53.3)    58                 32         8.3              9.8                 7.9

  Fonseca (2012)^43^         Yes                   12                         61                  III           361                    2              12                  186 (51.5)    53.7               31.9       8                9                   1.3‡

  Gallwitz (2012)a^44^       Yes                   16                         209                 III           1551                   2              104                 933 (60.2)    56.6               30.2       7.7              9.1                 715 (47.1)\*

  Gallwitz (2012)b^45^       Yes                   14                         128                 III           1029                   2              234†                524 (53.6)    56                 32.5       7.5              8.8                 5.7

  Garber (2009)^46^          Yes                   2                          138                 III           746                    3              52                  371 (49.7)    53                 33.1       8.3              9.4                 5.4

  Grunberger (2012)^47^      Yes                   7                          44                  II            164                    5              12                  74 (45.1)     56.6               32.1       7.3              NR                  3.9

  Haak (2012)^48^            Yes                   14                         133                 III           791                    6              24                  426 (53.9)    55.3               29.1       8.7              10.9                562 (74.3)\*

  Henry (2012)^49^           Yes                   8                          113                 III           326                    3              24                  170 (54.3)    54.1               32.6       8.1              9.4                 7.7

  Hollander (2011)^50^       Yes                   8                          133                 III           565                    3              76                  280 (49.6)    54                 30         8.3              9.0                 5.2

  Hollander (2012)^51^       Yes                   8                          63                  III           305                    2              24                  119 (40.8)    53.5               36.7       7.5              8.9                 5.1

  Inagaki (2012)^52^         No                    1                          NR                  III           427                    2              26                  290 (67.9)    56.8               26.1       8.5              NR                  9

  Kadowaki (2009)^53^        No                    1                          20                  II            153                    4              12                  104 (68.9)    60.3               25.3       8                9.2                 11.9

  Kaku (2010)^54^            No                    1                          49                  NR            264                    3              24                  169 (64)      59.7               24.9       8.4              9.5                 10.3

  Kikuchi (2010)^55^         No                    1                          29                  III           202                    2              12                  144 (71.3)    59.7               24.5       7.9              9.1                 9.2

  Kothny (2012)^56^          Yes                   13                         108                 NR            369                    2              52                  207 (56.1)    66.5               30.3       7.8              8.8                 16.6

  Marre (2009)^57^           Yes                   21                         116                 III           1041                   5              26                  516 (49.6)    56.1               29.9       8.4              9.8                 6.6‡

  Nauck (2009)^58^           Yes                   49                         NR                  II            306                    6              12                  143 (48.1)    55.7               32.7       7.9              NR                  5.3

  Nauck (2013) a^59^         Yes                   25                         187                 III           1049                   3              24                  549 (53.4)    57.7               32.4       8.3              11.1                9.3

  Nauck (2013)b^60^          Yes                   21                         170                 III           1091                   5              104                 635 (58.2)    56.7               31         8.4              10                  7.6

  NCT00082381 (2009)^61^     Yes                   13                         82                  III           551                    2              26                  306 (55.7)    58.9               31.4       8.2              10.2                9.6

  NCT00094770 (2009)^62^     Yes                   NR                         173                 III           1172                   2              104                 694 (59.2)    56.7               31.2       7.7              9.2                 6.4

  NCT00103857 (2009)^63^     Yes                   NR                         140                 III           915                    5              104                 539 (49.4)    53.5               NR         8.8              11.1                NR

  NCT00327015 (2009)^64^     Yes                   13                         211                 III           1306                   4              24                  643 (49.2)    52                 30.2       9.5              11.1                1.7

  NCT00328172 (2011)^65^     Yes                   6                          71                  II            302                    5              12                  175 (57.9)    57.3               31.1       8.3              10.5                NR

  NCT00395512 (2013)^66^     Yes                   23                         268                 III           655                    4              26                  320 (48.9)    52.6               31.1       8.8              10.6                3.2

  NCT00482729 (2009)^67^     Yes                   2                          229                 III           1250                   2              44                  708 (56.8)    49.7               NR         9.9              NR                  NR

  NCT00575588 (2010)^68^     Yes                   11                         130                 III           858                    2              104                 444 (51.7)    57.5               31.4       7.7              9                   5.4

  NCT00614939 (2011)^69^     Yes                   14                         75                  III           170                    2              52                  73 (42.9)     66.5               30.7       8.3              9.9                 16.7

  NCT00722371 (2011)^70^     NR                    NR                         NR                  III           1615                   7              54                  912 (56.5)    NR                 NR         NR               NR                  NR

  NCT00757588 (2011)^71^     Yes                   10                         72                  III           455                    2              52                  188 (41.3)    57.2               32.3       8.7              9.6                 11.9

  NCT00954447 (2012)^72^     Yes                   19                         167                 III           1261                   2              52                  658 (52.2)    60                 31         8.3              8.3                 NR

  NCT01137812 (2013)^73^     Yes                   17                         140                 III           755                    2              52                  422 (55.9)    56.5               NR         NR               NR                  NR

  NCT01204294 (2012)^74^     No                    1                          43                  III           352                    4              52                  246 (69.9)    61.3               NR         8                NR                  NR

  NCT01289119 (2013)^75^     No                    1                          30                  III           506                    6              16                  275 (54.3)    52.6               25.7       NR               NR                  4.1

  Pan (2012)^76^             Yes                   4                          40                  III           568                    2              24                  315 (55.5)    51.4               25.9       8.2              9.1                 1

  Pratley (2013)^77^         Yes                   17                         130                 III           760                    3              24                  362 (48.9)    56.4               32.7       8.3              10                  8.8

  Ratner (2010)^78^          Yes                   7                          133                 NR            542                    9              13                  270 (49.8)    56.2               31.9       7.5              8.8                 6.6

  Raz (2012)^79^             Yes                   NR                         53                  III           373                    3              24                  130 (36.7)    54.8               32.3       7.6              8.8                 2.4

  Rosenstock (2009) a^80^    Yes                   4                          118                 II            361                    10             16                  170 (47.8)    53.5               32.1       8                9.8                 4.9

  Rosenstock (2009) b^81^    Yes                   13                         110                 III           390                    3              26                  161 (41.3)    55.4               32.5       9.3              10.6                12.6

  Ross (2012)^82^            Yes                   9                          81                  II            491                    3              12                  280 (57.0)    58.6               29.6       8                9.2                 227 (47.5)\*

  Russell-Jones (2009)^83^   Yes                   17                         107                 III           581                    3              26                  326 (56.6)    57.5               30.5       8.3              NR                  9.4

  Russell-Jones (2012)^84^   Yes                   22                         124                 III           820                    4              26                  484 (59.0)    53.8               31.2       8.5              NR                  2.7

  Seino (2010)^85^           No                    1                          75                  III           411                    2              24                  268 (67)      58.3               24.5       8.9              11.3                8.2

  Seino (2012)a^86^          No                    1                          30                  III           288                    3              12                  198 (68.8)    52.6               25.9       8                NR                  6.3

  Seino (2012)b^87^          Yes                   4                          57                  III           311                    2              24                  149 (47.9)    58.4               25.3       8.5              7.7                 13.9

  Umpierrez (2011)^88^       Yes                   2                          39                  II            262                    2              16                  129 (36.4)    56.5               33.9       8.2              NR                  8.3

  Yang (2011)^89^            Yes                   3                          51                  NR            929                    4              16                  514 (55.3)    53.3               25.6       8.6              9.7                 7.5

  Zinman (2009)^90^          Yes                   2                          96                  III           533                    3              26                  302 (56.7)    55                 33.5       8.5              10.1                9
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BMI=body mass index; FPG=fasting plasma glucose; NR=not reported.

\*No (%) of patients with no more than 5 years' diabetes duration.

†Longest follow-up time (weeks).

‡Median duration of diabetes (years).

Twenty seven randomised controlled trials tested GLP-1 receptor agonists, 26 tested DDP-4 inhibitors, and two tested both agents; 17 tested incretin monotherapy, and 38 used incretin agents as add-on or combination treatment (table 2[](#tbl2){ref-type="table"}). Duration of treatment ranged from 12-107 weeks (median 26; 22 trials longer than 26 weeks).

###### 

 Intervention characteristics of randomised controlled trials of incretin treatment in patients with type 2 diabetes mellitus

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)              Drugs used across groups                                          Incretin                          Control   Follow-up from start of treatment\           
                                                                                                                                           (weeks)                                      
  -------------------------- ----------------------------------------------------------------- -------------- ------------------ --------- ------------------------------------ ------- -------
  Araki (2013)^36^           None                                                              Linagliptin    0/319                        Placebo                              0/80    12

  Linagliptin                0/319                                                                            Voglibose          0/162                                                  

  Barnett (2012)^37^         None                                                              Linagliptin    0/151                        Placebo                              0/76    18

  Bergenstal (2010)^38^      Metformin                                                         Exenatide      0/160                        Pioglitazone                         2/165   26

  Sitagliptin                0/166                                                                            Pioglitazone       2/165                                                  

  Bunck (2009)^39^           Metformin                                                         Exenatide      1/36                         Insulin glargine                     0/33    52

  Buse (2011)^40^            Insulin glargine ± metformin/pioglitazone (or both agents)        Exenatide      0/137                        Placebo                              0/122   30

  Chacra (2011)^41^          Glyburide                                                         Saxagliptin    0/501                        Placebo                              0/267   76

  Diamant (2010)^42^         Metformin ± SU                                                    Exenatide      1/233                        Insulin glargine                     0/223   26

  Fonseca (2012)^43^         None                                                              Lixisenatide   0/239                        Placebo                              0/122   12

  Gallwitz (2012)a^44^       Metformin                                                         Linagliptin    1/776                        Glimepiride                          0/775   104

  Gallwitz (2012)b^45^       Metformin                                                         Exenatide      1/511                        Glimepiride                          1/508   107\*

  Garber (2009)^46^          None                                                              Liraglutide    2/497                        Glimepiride                          0/248   52

  Grunberger (2012)^47^      None                                                              Dulaglutide    0/132                        Placebo                              1/32    12

  Haak (2012)^48^            None                                                              Linagliptin    0/428                        Placebo                              0/72    24

  Henry (2012)^49^           Metformin                                                         Taspoglutide   0/223                        Placebo                              0/101   24

  Hollander (2011)^50^       TZD                                                               Saxagliptin    1/381                        Placebo                              0/184   76

  Hollander (2012)^51^       Metformin                                                         Taspoglutide   0/154                        Placebo                              0/150   24

  Inagaki (2012)^52^         BG or BG + TZD                                                    Exenatide      0/215                        Insulin glargine                     0/212   26

  Kadowaki (2009)^53^        SU ± BG/TZD                                                       Exenatide      0/111                        Placebo                              0/40    12

  Kaku (2010)^54^            SU (glibenclamide, glicazide or glimeprimide)                     liraglutide    0/176                        Placebo                              0/88    24

  Kikuchi (2010)^55^         Glimepiride                                                       Vildagliptin   0/102                        Placebo                              0/100   12

  Kothny (2012)^56^          Untreated, insulin, OADs or any combination                       Vildagliptin   0/216                        Placebo                              0/153   52

  Marre (2009)^57^           Glimepiride                                                       Liraglutide    1/695                        Placebo                              0/114   26

  Liraglutide                1/695                                                                            Rosiglitazone      0/231                                                  

  Nauck (2009)^58^           Metformin                                                         Taspoglutide   0/248                        Placebo                              0/49    12

  Nauck (2013)a^59^          Metformin                                                         Taspoglutide   0/715                        Insulin glargine                     0/322   24

  Nauck (2013) b^60^         Metformin                                                         Liraglutide    1/724                        Placebo                              0/121   104

  Liraglutide                1/724                                                                            Glimepiride        1/242                                                  

  NCT00082381 (2009)^61^     Metformin + SU                                                    Exenatide      0/282                        Insulin glargine                     1/267   26

  NCT00094770 (2009)^62^     Metformin                                                         Sitagliptin    1/588                        Glipizide                            0/584   104

  NCT00103857 (2009)^63^     None                                                              Sitagliptin    1/551                        Metformin                            0/364   104

  NCT00327015 (2009)^64^     None                                                              Saxagliptin    0/978                        Metformin                            1/328   24

  NCT00328172 (2011)^65^     None                                                              Linagliptin    1/170                        Placebo                              0/67    12

  Linagliptin                1/170                                                                            Metformin          0/65                                                   

  NCT00395512 (2013)^66^     None                                                              Alogliptin     1/491                        Pioglitazone                         0/163   26

  NCT00482729 (2009)^67^     Metformin                                                         Sitagliptin    1/625                        No additional drug                   0/621   44

  NCT00575588 (2010)^68^     Metformin                                                         Saxagliptin    0/428                        Glipizide                            1/430   104

  NCT00614939 (2011)^69^     OADs and/or insulin                                               Saxagliptin    0/85                         Placebo                              1/85    52

  NCT00722371 (2011)^70^     None                                                              Sitagliptin    0/922                        Pioglitazone                         1/693   54

  NCT00757588 (2011)^71^     Insulin ± metformin                                               Saxagliptin    0/304                        Placebo                              0/151   52

  NCT00954447 (2012)^72^     Insulin and/or metformin and/or pioglitazone                      Linagliptin    3†/631                       Placebo                              1/630   52

  NCT01137812 (2013)^73^     Metformin + SU                                                    Sitagliptin    0/378                        Canagliflozin                        1/377   52

  NCT01204294 (2012)^74^     SU or A-GI                                                        Linagliptin    0/228                        Metformin                            0/124   52

  NCT01289119 (2013)^75^     None                                                              Alogliptin     0/252                        Placebo                              1/92    16

  Alogliptin                 0/252                                                                            Metformin          0/98                                                   

  Alogliptin                 0/252                                                                            Pioglitazone       0/63                                                   

  Pan (2012)^76^             None                                                              Saxagliptin    0/284                        Placebo                              0/284   24

  Pratley (2013)^77^         SU ± metformin                                                    Taspoglutide   1/494                        Pioglitazone                         0/257   24

  Ratner (2010)^78^          Metformin                                                         Lixisenatide   0/433                        Placebo                              0/109   13

  Raz (2012)^79^             None                                                              Taspoglutide   0/245                        Placebo                              0/123   24

  Rosenstock (2009) a^80^    None                                                              Exenatide      0/35                         Placebo                              0/51    16

  Albiglutide                0/270                                                                            Placebo            0/51                                                   

  Rosenstock (2009)b^81^     Insulin ± metformin                                               Alogliptin     2/260                        Placebo                              0/129   26

  Ross (2012)^82^            metformin                                                         Linagliptin    0/447                        Placebo                              0/44    12

  Russell-Jones (2009)^83^   Metformin + glimepiride                                           Liraglutide    0/230                        Placebo                              0/114   

  Liraglutide                0/230                                                                            Insulin glargine   0/232     26                                           

  Russell-Jones (2012)^84^   None                                                              Exenatide      0/248                        Metformin                            0/246   26

  Exenatide                  0/248                                                                            Pioglitazone       0/163                                                  

  Sitagliptin                1/163                                                                            Metformin          0/246                                                  

  Sitagliptin                1/163                                                                            Pioglitazone       0/163                                                  

  Seino (2010)^85^           None                                                              Liraglutide    0/268                        Glibenclamide                        0/132   24

  Seino (2012)a^86^          Metformin                                                         Alogliptin     0/188                        Placebo                              0/100   12

  Seino (2012)b^87^          Insulin ± SU                                                      Lixisenatide   0/154                        Placebo                              0/157   24

  Umpierrez (2011)^88^       Each of the two different classes (SU, biguanide, TZD or DPP-4)   Dulaglutide    2/196                        Placebo                              0/66    16

  Yang (2011)^89^            Metformin                                                         Liraglutide    0/697                        Glimepiride                          0/231   16

  Zinman (2009)^90^          Metformin + rosiglitazone                                         Liraglutide    0/356                        Placebo                              0/177   26
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

SU=sulfonylurea; TZD=thiazolidinedione; BG=biguanide; OADs=oral antidiabetic drugs.

\*Average treatment time (weeks); A-GI, alpha-glucosidase inhibitor.

†Pancreatitis events data extracted from additional information reported in ClinicalTrials.gov.

Thirty six randomised controlled trials (66%) adequately generated random sequence, 33 (60%) adequately concealed allocation (appendix 3); 47 (86%) blinded patients, caregivers, and outcome assessors. None of the trials adjudicated pancreatitis events.

Risk of pancreatitis in randomised trials
-----------------------------------------

Of the 55 randomised controlled trials reporting pancreatitis, 27 explicitly stated that no events of pancreatitis occurred during the course of study. Eight studies mentioned pancreatic enzymes; none, however, reported usable data. Overall, 37 pancreatitis events occurred in 33 227 patients who used at least one drug (raw event rate 0.11%). Results did not show a significant difference between incretins versus control (odds ratio 1.11, 95% confidence interval 0.57 to 2.17; fig 2[](#fig2){ref-type="fig"}).

![**Fig 2** Risk of pancreatitis events between patients with type 2 diabetes mellitus treated with incretin or control](lili017292.f2_default){#fig2}

When we explored the sources of heterogeneity, the risk did not differ by the type of incretin (GLP-1 agonists *v* DPP-4 inhibitors; interaction test P=0.99): 29 trials, involving 14 562 patients and 16 pancreatitis events (0.11%) compared GLP-1 agonists versus control (odds ratio 1.05, 95% confidence interval 0.37 to 2.94); 28 trials, involving 19 241 patients and 23 events (0.12%) compared DPP-4 inhibitors versus control (1.06, 0.46 to 2.45). Neither analysis suggested an increased risk of pancreatitis (fig A in appendix 4).

The subgroup analysis by type of control (that is, placebo *v* active drug) did not suggest apparent difference (odds ratio 1.27 in trials comparing with placebo, 1.00 in those comparing with active drug treatments; interaction P=0.72) (fig B in appendix 4). Exploration of the effect by the mode of treatment (monotherapy *v* add-on/combination treatment) also did not suggest significant difference (0.84 monotherapy *v* 1.22 add-on/combination treatment; interaction P=0.63) (fig C in appendix 4). Nor was there a difference by length of follow-up (interaction P=0.84; odds ratio 0.90 at 26 weeks or shorter *v* 1.44 at 26-52 weeks *v* 1.14 over 52 weeks) (fig D in appendix 4). The post hoc analysis of individual incretins did not show difference among those agents (fig E in appendix 4).

The sensitivity analysis using alternative effect measures (relative risk *v* odds ratio), statistical models (Mantel-Haenszel *v* Peto) and considerations on heterogeneity (random effect *v* fixed effect) did not show important change in the pooled effects (figs F-H in appendix 4).

Evidence from observational studies
-----------------------------------

Of the five observational studies, three retrospective cohort studies examined the risk of acute pancreatitis associated with the use of exenatide, sitagliptin, or both,[@ref91] [@ref92] [@ref93] and two case-control studies specifically assessed the risk of admission to hospital for acute pancreatitis in patients with type 2 diabetes taking incretins [@ref94] [@ref95] (tables 3[](#tbl3){ref-type="table"} and 4[](#tbl4){ref-type="table"}).

###### 

 Characteristics of observational studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus

  Author (year)           Study design                 Data source/country   Funding                Inclusion criteria                                                                                                                                                                                                                                                                                                                                            Exclusion criteria                                                                                                                                                                                                                                          No (%) male     Mean age (years)   Mean BMI   Mean HbA1c (%)   Mean FPG (mmol/L)   Mean diabetes duration (years)
  ----------------------- ---------------------------- --------------------- ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------- ------------------ ---------- ---------------- ------------------- --------------------------------
  Garg (2010)^91^         Retrospective cohort study   Claims data/US        NR                     Diabetic patients aged 18-63 years with pharmacy and medical claims data for continuous period of at least 12 months between 1 January 2007 and 30 June 2009                                                                                                                                                                                                  Patients aged \>63 because of possibility of incomplete medical data; patients with acute pancreatitis 6 months before or on index date; treatment with repaglinide, nateglinide, acarbose, or miglitol and treatment with both exenatide and sitagliptin   26953 (54.3)    52.7               NR         NR               NR                  NR
  Romley (2012)^92^       Retrospective cohort study   Claims data/US        Public funding         Patients having two or more medical claims with ICD-9 code of 250.xx within calendar year and fewer than two claims with ICD-9 code of 250.x1 within each year, using oral antidiabetes drugs at any point during study period, and enrolled for at least 1 year during 2007-09 with continuously enrolled throughout each year, with no gaps between years   Users of sitagliptin were patients aged \<18; patients with pancreatic cancer subsequent to incident cancer diagnosis; patients with occurrence of first event before 2007 or before first use of exenatide                                                 145560 (54.2)   63.1               NR         NR               NR                  3.1
  Sudhakaran (2011)^93^   Retrospective cohort study   Case records/India    No financial support   Asian Indian patients with type 2 diabetes in Indian tertiary diabetes care centre                                                                                                                                                                                                                                                                            NR                                                                                                                                                                                                                                                          3512 (63.2)     55.1               30.0       9.2              10.0                15.1
  Singh (2013)^94^        Case-control study           Claims data/US        Public funding         Type 2 diabetes mellitus patients who filled at least 1 prescription for any drug used to treat type 2 diabetes from 1 February 2005 to 31 December 2008; patients aged 18-64 on date of first code for diabetes, and contributed at least 6 months of medical or pharmacy coverage in calendar year with diabetes code, and of known sex                     Participants aged \>64 because of incomplete healthcare information; pancreatitis occurrences within 3 months of enrollment                                                                                                                                 1458 (57.5)     52                 NR         NR               NR                  NR
  Giorda (2013) ^95^      Case-control study           Claims data/Italy     Non-profit funding     Type 2 diabetes patients aged ≥41 who were dispensed at least one dose of any drug to treat diabetes between 1 Jan 2008 and 31 Dec 2012                                                                                                                                                                                                                       Individuals who had ICD-9-CM code for type 1 diabetes mellitus (250.x1 or 250.x3)                                                                                                                                                                           2750 (54.8)     72.2               NR         NR               NR                  NR

NR=not reported.

###### 

 Exposures, outcomes, and results of observational studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus

  Author (year)           Exposure of interest                                             Control group                                                                                                             Outcome measures                   No of events   Total No of patients   Adjusted estimates (95% CI)
  ----------------------- ---------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------- ---------------------------------- -------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Garg (2010)^91^         Exenatide, sitagliptin                                           Diabetic control group (new sulfonylurea, biguanide, or thiazolidinedione and no sitagliptin or exenatide prescription)   Acute pancreatitis                 154            38 615                 Exenatide *v* control: HR 0.9 (0.6 to 1.5); sitagliptin *v* control: HR 1.0 (0.7 to 1.3)
  Romley (2012)^92^       Exenatide                                                        Non-exenatide                                                                                                             Admission for acute pancreatitis   1 312          268 561                Exenatide *v* control: OR 0.93 (0.63 to 1.36)
  Sudhakaran (2011)^93^   Sitagliptin                                                      Insulin glargine                                                                                                          Acute pancreatitis                 0              5 560                  No events reported
  Singh (2013)^94^        Exenatide, sitagliptin                                           No sitagliptin or exenatide prescription                                                                                  Admission for acute pancreatitis   1 269          2 538                  Current use of sitagliptin or exenatide within 30 days before pancreatitis *v* no use: OR 2.24 (1.36 to 3.68); recent use past 30 days and \<2 years *v* no use: OR 2.01 (1.37 to 3.18); any use within 2 years *v* no use: OR 2.07 (1.36 to 3.13)
  Giorda (2013)^95^       Exenatide, liraglutide, sitagliptin, saxagliptin, vildagliptin   Not clearly reported                                                                                                      Admission for acute pancreatitis   1 003          5 015                  All incretin agents *v* control: OR 0.98 (0.69 to 1.38)

HR=hazard ratio; OR=odds ratio.

Of the three cohort studies, the first included 38 615 patients with diabetes (6545 exenatide, 15 826 sitagliptin, and 16 244 control) recruited in the US Medco National Integrated Database.[@ref91] Patients aged 18-63 were identified with ICD-9 code for drugs for type 2 diabetes and were followed up for a mean of 0.7 year (0.6 exenatide, 0.8 sitagliptin, 0.7 control). Exposure to incretins was probably identified from pharmacy claims. Study investigators computed a chronic disease score based on pharmacy claims data and identified risk factors for pancreatitis, including drugs and medical conditions by using pharmacy claims and ICD-9 codes. Acute pancreatitis was identified with ICD-9 codes; 154 pancreatitis events (0.4%) occurred (22 in the exenatide group (0.3%), 67 in the sitagliptin group (0.4%), 65 in the control group (0.4%)), with a corresponding incidence of 563.9 cases per 100 000 patient years (569.9 in the exenatide group, 554.4 in the sitagliptin group, and 571.9 in the control group). After adjustment for the influence of age, sex, history of pancreatic disease, alcohol intake, biliary stone disease, hypertriglyceridaemia, and chronic disease score, the risk of acute pancreatitis was similar between exenatide and control (adjusted hazard ratio 0.9, 95% confidence interval 0.6 to 1.5) and sitagliptin and control (1.0, 0.7 to 1.3).

The second study included 268 561 patients (530 574 patient years, 13 791 patient years in exenatide group, 516 783 non-exenatide) with type 2 diabetes from an employer-provided health insurance covering about 6.6 million employees in the US.[@ref92] Patients were aged 63.1 on average, with mean duration of diabetes of 3.1 years. Study investigators used ICD-9 codes to identify patients with type 2 diabetes and their pancreatic outcome (admission for acute pancreatitis, code 577.0). The information regarding exposure to exenatide was identified by National Drug Codes. They also used ICD-9 codes to identify information regarding a set of 19 co-morbid conditions (such as congestive heart failure, chronic obstructive pulmonary disease, and stroke) and traditional risk factors for pancreatitis. They identified 1312 (0.5%) admissions for acute pancreatitis events (27 in those taking exenatide, 1285 in those not taking exenatide), with corresponding incidence of 247.3 cases per 100 000 patient years (195.8 for exenatide, 248.7 for non-exenatide). The risk of admission for acute pancreatitis in patients who have used exenatide was not statistically different (0.20% *v* 0.25%; adjusted odds ratio 0.93, 95% confidence interval 0.63 to 1.36) after adjustment for age, sex, years since diagnosis of diabetes, year of observation, 19 co-morbid conditions, and traditional risk factors for pancreatitis.

The third study recruited 5560 patients from a diabetes specialty care centre in India.[@ref93] Of these patients, 2817 received sitagliptin and 2743 self injected insulin glargine. Information regarding ascertainment of other variables (confounders), however, was not reported. This study found no patient with either symptoms or signs of acute pancreatitis in the sitagliptin or insulin glargine group.

The first case-control study identified 1269 cases (admissions for acute pancreatitis) and 1269 controls from administrative claims of Blue Cross Blue Shield plan.[@ref94] All of these patients, aged 52 on average, had type 2 diabetes, as confirmed by ICD-9 codes or drug history for hyperglycaemia. Patients with type 1 diabetes or gestational diabetes were excluded. Cases were identified with a validated algorithm based on ICD-9 and current procedural terminology codes for acute pancreatitis, and occurrences of pancreatitis within three months of enrolment were excluded. Controls were selected, on a 1:1 ratio, for each case; they were matched for age within 10 years, sex, insurance plan site, diabetes complication severity index, and enrolment pattern or duration of follow-up. Information on drug exposure (exenatide or sitagliptin) was identified from the pharmacy database. No information was available regarding the ascertainment of risk factors for acute pancreatitis and use of other drugs. After we controlled for the influence of hypertriglyceridaemia, alcohol use, gallstones, tobacco abuse, obesity, biliary and pancreatic cancer, cystic fibrosis, an indicator of general morbidity level, and metformin exposure during the same period, we found that use of sitagliptin or exenatide within 30 days before pancreatitis versus non-use (that is, no use for more than two years before the index date of pancreatitis event; adjusted odds ratio 2.24, 95% confidence interval 1.36 to 3.68), recent use (30 days to two years before admission; 2.01, 1.37 to 3.18), and any use within two years (2.07, 1.36 to 3.13) were associated with significantly increased odds of acute pancreatitis.

The second case-control study, conducted in Italy, assessed the use of incretins (exenatide, liraglutide, sitagliptin, saxagliptin, and vildagliptin).[@ref95] This study identified 1003 cases (admission for acute pancreatitis) and 4012 controls matched for year of birth, sex, and year of first exposure to antidiabetic drugs from regional administrative data of the Italian national health system that allowed the linkage of drugs dispensed with hospital discharges. All the patients with type 2 diabetes, dispensed at least one dose of antidiabetic drugs and aged 72 on average, were identified according to the ICD-9 system. Patients coded for type 1 diabetes (250.x1, 250.x3) were excluded. Cases were identified through the ICD-9 code (577.0) at discharge. The exposure to incretins and other antidiabetic drugs (metformin or glibenclamide) was measured according to the anatomical therapeutic classification system. Potential confounders---history of chronic or acute pancreatitis, gallstones, alcohol misuses, biliary tract or pancreatic cancers, and admission for cardiovascular diseases and diabetic retinopathy---were measured with ICD-9 codes. After adjustment for those confounders and the use of other antidiabetic drugs, the adjusted analyses did not show a significant association between the exposure to incretins and the risk of admission for acute pancreatitis (adjusted odds ratio 0.98, 95% confidence interval 0.69 to 1.38).

Risk of bias in observational studies
-------------------------------------

All observational studies used either claims data or patients' medical records for their analyses. Studies using claims data or medical records confirmed diagnosis of type 2 diabetes, drug exposures, confounding factors, and occurrence of pancreatitis based on ICD-9 codes and pharmacy claims data (tables 5 and 6[](#tbl5){ref-type="table"} [](#tbl6){ref-type="table"}). The approaches for ascertaining type 2 diabetes differed across those studies (the ICD-9 codes they used varied), and the accuracy of ascertaining type 2 diabetes remains unclear. Three studies described the method for ascertaining confounding factors and the use of drugs other than incretins.[@ref91] [@ref92] [@ref95] Though the four studies that used claims data adjusted for the association, they chose different variables, leaving the adequacy of adjustment questionable. All studies failed to report the extent to which the claims data were complete in the overall database. Because of these limitations the risk of bias associated with eligible observational data was moderate to high.

###### 

 Risk of bias of cohort studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus

  Author (year)           Ascertainment of type 2 diabetes conditions                                                                                                                             Ascertainment of exposure to incretin agents                                   Selection of non exposed cohort                Ascertainment of other confounding variables                                                                                                  Demonstration that outcome of interest not present at start of study                    Comparability of study controls for important factors                                                                                                                                                       Assessment of outcome                                                             Completeness of outcome and exposure variables
  ----------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------ ---------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------- ------------------------------------------------------------------------------
  Garg (2010)^91^         Patients with diabetes identiﬁed by presence of at least 1 ICD-9 code of 250.XX and claim for new antidiabetes drugs                                                    Statement not explicit; likely from new antidiabetes drug of pharmacy claims   Drawn from same population as exposed cohort   Risk factors for acute pancreatitis determined from ICD-9 claims data                                                                         Yes, patients with acute pancreatitis 6 months before or on index date were excluded    Cox proportional hazard model built to control for age, sex, hypertriglyceridaemia, alcohol abuse, biliary stone disease, cholestatic liver disease, and drug therapy                                       Acute pancreatitis determined by claim for ICD-9 code 577.0                       Completeness of outcome and exposure variable data in database not mentioned
  Romley (2012)^92^       Patients with type 2 diabetes identified with ICD code (250.XX and 250.X1) and with use of antidiabetes drugs identified by National Drug Code within pharmacy claims   Exenatide use identified by National Drug Code within pharmacy claims          Drawn from same population as exposed cohort   Co-morbid conditions and traditional pancreatitis risk factors, such as history of gallstones or alcohol abuse, identified from ICD-9 codes   Yes, patients excluded if pancreatitis occurred before enrolment and use of exenatide   Logistic analyses used to control for influence of age, sex, years since diabetes diagnosis, 19 co-morbid conditions, and traditional risk factors for pancreatitis (such as gallstones or alcohol abuse)   Admission for pancreatitis identified by inpatient claims with ICD-9 code 577.0   Completeness of outcome and exposure variable data in database not mentioned
  Sudhakaran (2011)^93^   Patients with type 2 diabetes prescribed sitagliptin or insulin glargine identified from medical records                                                                Statement not explicit; likely from medical records                            Drawn from same population as exposed cohort   Not reported                                                                                                                                  Not reported                                                                            No, patients had significant difference in age, sex, BMI, duration of diabetes between sitagliptin and insulin glargine, and no adjusted analysis conducted                                                 Medical records                                                                   All patients with complete follow up

###### 

 Risk of bias in case-control studies of incretin treatment and pancreatitis in patients with type 2 diabetes mellitus

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Author (year)       Ascertainment of type 2 diabetes conditions                                                                                                                              Is case definition adequate                                                                                                                                                  Selection of controls                                                                                                                                                                  Definition of controls                Ascertainment of exposure to incretin agents                                                                                                                                                                                                Ascertainment of other confounding variables                                                                                                                                                                                                                                                         Same method of ascertainment for exposure to incretin agents                                                                                                                                                                                                                       Comparability of study controls for important factors                                                                                                                                                                                                          Completeness of data within database
  ------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------
  Singh (2013)^94^    Type 2 diabetes mellitus identified as 1 relevant inpatient code of ICD-9 or 2 outpatient ICD-9 codes separated by at least 30 days (250.xx, 648.0, 362.0, and 266.41)   Yes, presumptive cases identified with validated\                                                                                                                            Each case randomly selected 1 control subject from\                                                                                                                                    Patients with no acute pancreatitis   Drug exposure defined as having filled prescription for sitagliptin or exenatide before first observed diagnosis of pancreatitis, and prescription data used as indicator of drug exposure                                                  Ascertainment of risk factors for acute pancreatitis not mentioned                                                                                                                                                                                                                                   Yes, both groups used drug use information from computerised pharmacy database containing date of prescription filled and supplied to determine exposure to sitagliptin or exenatide, and patient with exposure after index diagnosis of acute pancreatitis counted as unexposed   Logistic regression model used control for matching variables, potential confounders specified a priori and identifiable in claims data, and metformin exposure during same period                                                                             Both groups had same rate of missing information on sex
                                                                                                                                                                                               algorithm of ICD-9 and Current Procedural Terminology codes for acute pancreatitis                                                                                           same population matched on age within 10 years, sex, insurance plan site, diabetes complication severity index (0, 1, 2, 3, or more), and enrolment pattern or duration of follow-up                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            

  Giorda (2013)^95^   Patients with type 2 diabetes identified as at least 1 dose of any drug to treat diabetes and patients with type 1 diabetes excluded by ICD-9 code ( 250.x1 or 250.x3)   Yes, cases identified by having at least one discharge for acute pancreatitis (ICD-9 code 577.0 discharge diagnosis at any time after ﬁrst exposure to antidiabetic drugs)   Each case randomly selected four controls from same population source, matched for year of birth, sex, and year of ﬁrst exposure to antidiabetic drugs                                 Patients with no acute pancreatitis   Incretins selected by anatomical therapeutic chemical (ATC) classiﬁcation system (ATC codes A10BH01 and A10BD07 (sitagliptin), A10BH02 and A10BD08 (vildagliptin), A10BH03 (saxagliptin), A10BX04 (exenatide), and A10BX07 (liraglutide))   Potential confounders identified from ICD-9 codes, such as chronic or acute pancreatitis (excluding episode of index case (ICD-9 code 577.0)), gallstones, alcohol misuse, hypertriglyceridaemia, obesity, biliary tract or pancreatic cancers, cardio vascular diseases, and diabetic retinopathy   Yes, both cases and controls who had been prescribed incretins identified with regional drug database                                                                                                                                                                              Logistic regression model built to control for confounders, including past history of pancreatitis, gallstones, alcohol use, hypertrigly ceridaemia, obesity, biliary tract or pancreatic cancer, cardiovascular disease, and metformin or glibenclamide use   Authors did not mention completeness of outcome and exposure variable data in database
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Discussion
==========

Main findings
-------------

In this systematic review and analysis of 55 randomised trials (low to moderate risk of bias involving 37 cases of pancreatitis among 33 227 patients), three retrospective cohort studies (moderate to high risk of bias involving 1466 pancreatitis events among 312 736 patients), and one case-control study (moderate risk of bias involving 1003 patients admitted to hospital for acute pancreatitis) we found no evidence to suggest an increased risk of pancreatitis associated with the use of incretins in patients with type 2 diabetes. The other case-control study (1269 patients admitted for acute pancreatitis), at moderate risk of bias, reported increased risk of admission for pancreatitis associated with the use of sitagliptin or exenatide.

The incidence of pancreatitis was low. In randomised trials, pancreatitis occurred in 0.11% of patients (0.11% in those taking incretins; 0.11% in control patients). In cohort studies, the risk of acute pancreatitis and admission for pancreatitis was higher (0.47%) than the risk in randomised trials, potentially because of a higher incidence of risk factors such as gallstones and longer follow-up.

Our findings should be interpreted cautiously. Although we included a large number of randomised trials, those trials were typically designed for testing efficacy. Many had relatively small sample sizes and relatively short follow-up. Because pancreatitis is rare and the event rates low, the confidence intervals around relative effects are wide, leaving the possibility of an undetected increase in risk. Furthermore, these trials---mostly phase III studies---often recruited patients with less co-morbidity than patients seen in clinical practice. The risk in the non-exposed patient group is therefore lower than usual (as above 0.11% in trials *v* 0.47% in observational studies). This in part explains the wide confidence intervals and also limits generalisability of the results.

There are further potential limitations of the randomised trials. Trials could have failed to document pancreatitis events or, if documented, failed to report these events (that is, selective reporting bias). Pancreatitis, however, is usually considered a serious adverse event in trials of type 2 diabetes, and, according to FDA's policy, the reporting of serious adverse event data is mandatory to ClinicalTrials.gov,[@ref27] limiting the risk of lack of monitoring and selective reporting. Even if pancreatitis events were monitored, however, they might not have been independently adjudicated, raising the possibility of inaccurate data.

A final issue is the possibility of failure to identify patients with subclinical minimally symptomatic pancreatitis. The increase of pancreatic enzyme activity (lipase and amylase), a surrogate measure, could represent supporting evidence in the assessment of the risk of pancreatitis; these data, however, were not readily usable.

The five observational studies, involving patients in real practice, had large sample sizes, but had limitations related to use of claims data or patients' medical records. Because most studies relied on the ICD-9 coding system to identify study populations and outcomes, the ascertainment of type 2 diabetes, and particularly pancreatitis, was probably inadequate because of the variation of diagnosis criteria and lack of outcome adjudication. Similar to the situation with trials, subclinical and minimally symptomatic cases of pancreatitis were less likely to be identified in those studies. Additionally, the exposure to incretins and control drugs and the exposure to other confounding factors might not have been accurately documented. The completeness of data within each of those databases is also unclear; investigators might have excluded those without complete exposure and outcome data from analyses. Finally, the accurate measurement and adjustment for other prognostic factors was limited. Overall, the risk of bias was moderate to high in all observational studies.

Among those five observational studies, a single case-control study suggested an increased risk of admissions for acute pancreatitis; the four others, including three cohort studies and one case-control study, did not. Of the four studies suggesting no increased risk, three consistently reported the point estimates close to 1 and the confidence intervals were similar (0.6 to 1.5). The reasons for discrepancy between the single case-control study and the other studies are not clear: the selection of different study populations (that is, different age groups, thus differing baseline risk) and different choices of exposures and non-exposures are possible explanations. Varying risk of bias and inadequate control of confounders are other explanations.

In addition to those five eligible observational studies, three retrospective cohort studies (appendix 2), at moderate risk of bias and that failed to limit patients to those with type 2 diabetes (and were therefore excluded), reported the risk of acute pancreatitis associated with exenatide.[@ref96] [@ref97] [@ref98] These studies consistently suggested that exenatide was not associated with an increased risk of acute pancreatitis.

The FDA adverse drug event system has documented 2327 spontaneously reported cases of pancreatitis in patients taking exenatide, 888 case in those taking liraglutide, 718 cases in those taking sitagliptin, and 125 cases in those taking saxagliptin.[@ref12] The number of cases of pancreatitis seemed larger in those taking incretins than other active antidiabetic drugs, suggesting a potentially increased risk. The absence of data on number of patients exposed to those antidiabetic drugs, and the possibility of a lower threshold of reporting with new drugs, however, severely limits the usefulness of these data for making causal inferences.

Strengths and limitations
-------------------------

Our study has several strengths. Firstly, we systematically identified and included both randomised and non-randomised studies to examine the risk of pancreatitis associated with incretin treatment. Secondly, in addition to published reports, we searched ClinicalTrials.gov, which provided additional outcome information and eligible trials. Thirdly, we instituted a rigorous approach to ensure the data were accurate, in particular using the data on pancreatitis reported in ClincialTrials.gov and journal publications for consistency.

We did not assess the risk of pancreatic cancer associated with the use of incretins. Although studies have suggested a potentially increased risk, they have many limitations.[@ref99] The FDA adverse drug event system documented 258 cases of pancreatic cancer in patients taking exenatide, 63 cases in those taking liraglutide, 81 cases in those taking sitagliptin, and 18 cases in those taking saxagliptin.[@ref12] The number of cancer cases did not seem larger in patients taking incretins (except exenatide) than other drugs for diabetes. We also did not specifically assess the risk of chronic pancreatitis associated with the use of incretins; few data on this issue are available.

Comparison with other studies
-----------------------------

Two other meta-analyses have assessed the risk of pancreatitis among patients using incretins, one examining GLP-1 agonists[@ref100] and another DPP-4 inhibitors.[@ref101] The first meta-analysis, involving 22 randomised controlled trials and three retrospective cohort studies, reported no significant association between pancreatitis events and the exposure to exenatide or liraglutide.[@ref100] This analysis pooled results of randomised trials and large observational studies, making the interpretation of estimates challenging: in 10 randomised controlled trials and three retrospective cohort studies the odds ratio for exenatide was 0.84 (95% confidence interval 0.58 to1.22) and in the combined results of 10 randomised controlled trials the odds ratio for liraglutide was 0.97 (0.21 to 4.39). Furthermore, this study included two cohort studies, in which patients might not be strictly limited to those with type 2 diabetes mellitus and were thus excluded from our review. The second study was a meta-analysis of exclusively randomised controlled trials, investigated risk of pancreatitis in DDP-4 inhibitors.[@ref101] It found that DPP-4 inhibitors were not associated with an increased risk of pancreatitis (odds ratio 0.93, 95% confidence interval 0.51 to 1.69).[@ref101] Both meta-analyses included trials that had no explicit information regarding pancreatitis; they might have assumed that no pancreatitis occurred in such trials. It is probably reasonable to assume no event in the absence of reporting in such situation. This approach, however, could artificially reduce the incidence of pancreatitis as more patients are added to the population whereas no events are added. In either of the approaches (ours and those of the two other published meta-analyses), however, the statistical model did not include zero event trials in meta-analyses, as they are statistically omitted in pooling relative effects. Compared with these two meta-analyses, our study included five observational studies that carry more important information regarding the risk of pancreatitis.

Conclusion
----------

In summary, the available evidence suggests that the incidence of pancreatitis in patients taking incretins is low and that these drugs do not increase the risk of pancreatitis. The current body evidence, however, is not definitive, and more carefully designed and conducted observational studies are warranted to definitively establish the extent, if any, of increased risk. In addition, incretins, which are expensive, are no superior to widely used antidiabetic drugs (such as metformin) for glucose control. Given the uncertainty about the effect of incretins on important outcomes, including pancreatitis, the lack of apparent benefits in glucose control over other drugs, and the relatively high costs, the use of incretins might not be preferable to other available antidiabetic drugs.

Future demonstration of consistency of the putative association across studies is warranted. Trialists exploring the effect of incretins should report all adverse events affecting the pancreas. Presentation of associations both in class of agents (such as GLP-1 agonists) and individual incretins is important and informative to assess the potential risk. Reporting of results for the gradient of pancreatic outcomes---pancreatic enzymes, asymptomatic pancreatitis, symptomatic pancreatitis, and admission for acute pancreatitis---will also be helpful for informing risks associated with incretin treatment. Future randomised trials that specifically examine this issue, however, are unlikely. We need more carefully designed and conducted observational studies that clearly define study population, accurately collect information regarding length to follow exposure and confounding factors, completely collect outcome data, and adequately adjust for the influence of confounders. Currently, a European study is applying surveillance and observational study methods to assess vascular and pancreatic safety of diabetes drugs, including thiazolidinedones (TZDs), incretins, and amylin analogues in people with type 2 diabetes.[@ref102] The resulting findings might provide more definitive evidence.

### What is already known on this topic

1.  A number of cases of acute pancreatitis have been reported in patients with type 2 diabetes who were taking incretins

2.  Concerns have arisen regarding the risk of pancreatitis associated with these agents, though findings from various studies are conflicting

### What this study adds

1.  Data from randomised controlled trials are not adequate to assess the risk of pancreatitis, but several large observational studies, with methodological limitations, provide relatively precise estimates

2.  The available evidence suggests that the incidence of pancreatitis in patients with type 2 diabetes taking incretins is low and that incretins do not increase risk of pancreatitis
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